BHCM
KROS icon

Brevan Howard Capital Management’s Keros Therapeutics KROS Stock Holding History

Brevan Howard Capital Management’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-14,651
Closed -$162K – 2346
2026
Q1 		$162K Buy
+14,651
New +$226K ﹤0.01% 1945
2025
Q4 		– Sell
-44,874
Closed -$710K – 2067
2025
Q3 		$710K Sell
44,874
-25,275
-36% -$373K ﹤0.01% 1090
2025
Q2 		$936K Buy
70,149
+4,305
+7% +$58.1K 0.01% 1100
2025
Q1 		$671K Buy
65,844
+54,658
+489% +$635K 0.01% 636
2024
Q4 		$177K Buy
11,186
+5,468
+96% +$284K ﹤0.01% 928
2024
Q3 		$332K Buy
+5,718
New +$282K ﹤0.01% 811

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Brevan Howard Capital Management's KROS Position: Q2 2026 in Review

Brevan Howard Capital Management sold out of Keros Therapeutics (KROS) in Q2 2026, closing a stake of 14,651 shares — an estimated $162K sold.

Brevan Howard Capital Management first reported a position in KROS in Q3 2024 and held it in 6 quarters. The position peaked at $936K in Q2 2025. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Brevan Howard Capital Management reported no remaining Keros Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Brevan Howard Capital Management sold 14,651 Keros Therapeutics shares in Q2 2026, an estimated $162K.
  • Brevan Howard Capital Management first reported a position in Keros Therapeutics in Q3 2024 and held it in 6 quarters.
  • Brevan Howard Capital Management's Keros Therapeutics position peaked at $936K in Q2 2025.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.